Northwell Health Cancer Institute Joins Innovative Cancer Trial
The Northwell Health Cancer Institute has officially begun enrolling patients in the pivotal Phase III TIGeR-PaC clinical trial, marking a significant advancement in the search for more effective treatments for locally advanced pancreatic cancer (LAPC). RenovoRx, a pioneering name in innovative oncology therapies, aims to achieve full patient enrollment by mid-2025, and the inclusion of such a reputable facility underscores the importance of this study.
What You Need to Know About the TIGeR-PaC Trial
The TIGeR-PaC study evaluates the cutting-edge TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform, which represents a breakthrough in delivering targeted chemotherapy directly to tumors. This method allows for a localized infusion of gemcitabine, potentially increasing the drug’s effectiveness while minimizing systemic side effects, a concern with traditional intravenous methods.
Transformative Potential of TAMP Therapy
Dr. Daniel King, MD, PhD at Northwell Health, expressed enthusiasm about joining the study, noting, "We are excited to contribute to a trial that could revolutionize pancreatic cancer treatment." His insights reflect the innovative nature of TAMP as a targeted approach for chemotherapy delivery, designed to improve patient outcomes significantly.
Collaboration with Esteemed Institutions
RenovoRx’s partnership with Northwell Health is a landmark achievement. According to Leesa Gentry, Chief Clinical Officer of RenovoRx, this collaboration not only enhances their ability to recruit patients rapidly but also elevates the potential impact of the trial across the nation. As one of the largest healthcare systems in the area, NHCI's involvement places RenovoRx in a prime position to leverage advanced healthcare resources and expertise.
Understanding Locally Advanced Pancreatic Cancer
Locally advanced pancreatic cancer (LAPC) is a challenging condition often diagnosed when the cancer has progressed but is not yet metastatic. This form of cancer can be particularly aggressive, and current treatment options are limited. Statistics from reputable health organizations reveal that the 5-year survival rate for pancreatic cancer is a sobering 13%, highlighting the urgent need for new therapies in this arena.
RenovoRx and Its Innovative Therapeutics
RenovoRx is committed to addressing substantial gaps in cancer treatment with its FDA-cleared RenovoCath® delivery system. This device is designed to deliver treatments directly to the tumor site, enhancing the efficacy of drugs like gemcitabine. The ongoing investigation into this combination product signifies a forward leap in oncology therapeutics, with the potential to change how clinicians approach complex malignancies.
Ongoing Developments and Future Steps
The TIGeR-PaC trial features multiple interim analyses to monitor progress, with ongoing evaluations expected to guide future directions. The first interim review occurred in early 2023, with positive recommendations for continued study. As patient enrollment progresses, results from the ongoing trial will become critical in assessing TAMP’s efficacy and safety compared to standard care.
Potential for Enhanced Patient Outcomes
The clinical trial is not just about gathering data; it represents hope for patients facing this diagnosis. With a focus on overall survival benefits, the outcomes from this trial could provide invaluable insights into managing LAPC more effectively.
Frequently Asked Questions
What is the TIGeR-PaC clinical trial?
The TIGeR-PaC trial is a Phase III multi-center study evaluating a new therapy for locally advanced pancreatic cancer using an innovative drug delivery system.
What is the goal of the trial?
The trial aims to assess the efficacy and safety of the TAMP therapy platform in improving treatment outcomes for LAPC patients compared to standard chemotherapy.
Who is involved in the trial?
The Northwell Health Cancer Institute is one of the key participating clinical sites, alongside other prominent cancer treatment centers across the country.
When is patient enrollment expected to be completed?
RenovoRx aims to reach full patient enrollment in the trial by the first half of 2025.
What is RenovoCath?
RenovoCath is RenovoRx's FDA-cleared device designed for localized drug delivery, allowing for targeted therapy directly to cancer sites while minimizing systemic exposure.
